A randomized, single-center, open-label, two-period cross-over, pharmacokinetic study, to evaluate the bioequivalence of a single 40 mg H 199/18 dose administered as an intact capsule and as an open capsule in healthy male and female volunteers.
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
No locations available